Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Hosted on MSN1mon
CA thumbs down Sanofi’s appeal on DengvaxiaMANILA, Philippines — French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia dengue vaccine has been denied by the Court of ...
The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.
Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...
Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...
Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...
Hosted on MSN14h
PAI Partners raises offer for Sanofi's consumer unit - reportsPAI Partners increased its offer for Sanofi's (NASDAQ:SNY) consumer health unit. The private equity shop raised its offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback